Developer · Switzerland

Synendos Therapeutics AG

Private clinical-stage neuroscience company based in Basel, Switzerland, incorporated in April 2019 as a spin-out of the University of Bern. It develops Selective Endocannabinoid Reuptake Inhibitors (SERIs), a new class of endocannabinoid-system modulators, for anxiety, mood and stress-related disorders. Lead asset SYT-510 is in Phase 2 in generalized anxiety disorder.

synendos.com ↗

1compound
1program
1indication
Phase 2lead asset

Phase distribution

  • Phase 21

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Catalysts · 1 upcoming · 1 reported

  • Early 2027Anticipated

    SYT-510forGeneralized anxiety disorderTopline data

    Preliminary data from the Phase 2a single-dose crossover study of SYT-510 in generalized anxiety disorder (amygdala fMRI response and defensive-behaviour endpoints), guided for early 2027.

    NCT07478744source ↗

Recently reported

  • 2025-09-24met

    SYT-510forGeneralized anxiety disorderTopline data

    Phase 1 SAD/MAD topline in healthy volunteers: no drug-related safety concerns, plasma and CNS exposure at anticipated pharmacological levels, EEG effect consistent with anxiolytic medicines.

    source ↗

Recent activity

  • Apr 22, 2026Phase changeSYT-510·Generalized anxiety disorderPhase 2Phase 2a NCT07478744 started (actual start date per ClinicalTrials.gov); Synendos publicly announced the start of dosing on 2026-05-20.source ↗
  • Sep 24, 2025ReadoutSYT-510·Generalized anxiety disordermetPhase 1 SAD/MAD topline in healthy volunteers: no drug-related safety concerns, plasma and CNS exposure at anticipated pharmacological levels, EEG effect consistent with anxiolytic medicines.source ↗
  • Jan 18, 2024Phase changeSYT-510·Generalized anxiety disorderPhase 1Synendos announced EMA authorisation to begin the Phase 1 first-in-human, randomized, double-blind, placebo-controlled single-ascending-dose study of SYT-510 in healthy adults. The SAD study is not registered on ClinicalTrials.gov and its first-dosing date is not disclosed, so this authorisation date is a lower bound for entry into Phase 1.source ↗

Trials recruiting · 1 recruiting of 2 sponsored

  • Phase 2SYT-510n=241 site · United Kingdom

    A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder

    Generalized Anxiety DisorderNCT07478744 ↗

Competitive landscape

Other companies developing against Synendos Therapeutics AG's targets or indications.